Rare Tumor Trials
The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.
Status: Recruiting | Phase: Not Applicable
Official Title: Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors)
Study Purpose: To evaluate the effectiveness of treating patients with rare cancers with two immunotherapy drugs: nivolumab and ipilimumab. Learn more.